Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027033 | PMC |
| http://dx.doi.org/10.1097/HS9.0000000000000871 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
T follicular helper cells (T): From physiological to pathological aging.
Eur J Intern Med
September 2025
Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy; Istituti Clinici Scientifici ICS Maugeri - S.p.A.-Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Scientifico di Telese Terme, Telese, Italy. Electronic address:
The fraction that the elderly represent in the world's population is growing rapidly; numerous alterations that impact all organs and systems, including the immune system, are related to aging. A complex process common in the elderly, known as immunosenescence, is characterized by a decreased ability to respond to vaccination as well as an increased risk of bacterial and viral infections, autoimmune, cardiovascular and neurodegenerative diseases. These processes are associated with alterations in the innate and adaptive immune system and lead to a condition of chronic low-grade inflammation, referred to as inflammaging.
View Article and Find Full Text PDFPre-transplant compatibility testing: Transition from CDCXM to flow cytometry in India.
Transpl Immunol
September 2025
Molecular and Transplant Immunology Laboratory, Department of Transfusion Medicine (Blood Center), Medanta-The Medicity, Gurgaon, Haryana, India.
Over 60 % of kidney transplant candidates are non-sensitised while remaining 40 % are sensitised because of previous exposure to human alloantigens during previous transplants, blood transfusions, and pregnancy in women. Pre-transplant compatibility testing is mandatory prior to renal transplantation for detecting the presence of donor-specific antibodies (DSAs), which are associated with early hyperacute/acute and later chronic rejections. Initially, complement-dependent cytotoxicity crossmatch (CDCXM) was used as a traditional method for detecting preformed DSAs.
View Article and Find Full Text PDFInfluence of amitriptyline therapy on T cell phenotype in chronic pain patients.
Biomed Pharmacother
September 2025
Institute of Medical Microbiology, University Hospital Essen, University Duisburg-Essen, Germany.
Chronic pain (CP) is a major health issue globally, affecting millions and resulting in a significant healthcare burden. Although amitriptyline is widely used to manage CP, its immunomodulatory effects during pain therapy, especially on T cell phenotypes, remain unclear. In this study, we explored how amitriptyline alters T cell phenotypes in CP patients.
View Article and Find Full Text PDFAdvancement of clinical practice in delivering CAR T-cell therapy: impact on healthcare resource utilization and comparison with autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas.
Ann Hematol
September 2025
Institute for Workflow-Management in Health Care, European University of Applied Sciences, Cologne, Germany.
In patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who are either refractory to first-line therapy or relapse within 12 months, chimeric antigen receptor (CAR) T-cell therapy is more effective than salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) as second-line therapy. Adoption of CAR T-cell therapy into routine clinical practice involves a period of adaptation and refinement of clinical processes. We aimed to document the evolution of clinical processes for CAR T-cell therapy during 2022 and 2023, and compare healthcare resource utilization (HCRU) associated with CAR T-cell and ASCT processes in routine clinical practice.
View Article and Find Full Text PDFPopulation Pharmacokinetics of Valemetostat and Exposure-Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma.
J Clin Pharmacol
September 2025
Daiichi Sankyo Inc., Basking Ridge, NJ, USA.
Valemetostat is a dual inhibitor of EZH2/1 approved in Japan for the treatment of relapsed/refractory (R/R) adult T-cell lymphoma/leukemia (ATLL) and R/R peripheral T-cell lymphoma (PTCL). It is administered orally once daily (QD) at 200 mg. Here, we present comprehensive population pharmacokinetic (PPK) and exposure-response (ER) analyses of valemetostat.
View Article and Find Full Text PDF